95 related articles for article (PubMed ID: 12460028)
21. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
22. Update on adverse drug events associated with parenteral iron.
Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
Nephrol Dial Transplant; 2006 Feb; 21(2):378-82. PubMed ID: 16286429
[TBL] [Abstract][Full Text] [Related]
23. Parenteral iron therapy in obstetrics: 8 years experience with iron-sucrose complex.
Perewusnyk G; Huch R; Huch A; Breymann C
Br J Nutr; 2002 Jul; 88(1):3-10. PubMed ID: 12117422
[TBL] [Abstract][Full Text] [Related]
24. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
25. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
[TBL] [Abstract][Full Text] [Related]
26. Improving efficiency and value in health care. Intravenous iron management for anaemia associated with chronic kidney disease: linking treatment to an outpatient clinic, optimizing service provision and patient choice.
Bhandari S; Naudeer S
J Eval Clin Pract; 2008 Dec; 14(6):996-1001. PubMed ID: 18785894
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers.
Danielson BG; Salmonson T; Derendorf H; Geisser P
Arzneimittelforschung; 1996 Jun; 46(6):615-21. PubMed ID: 8767353
[TBL] [Abstract][Full Text] [Related]
28. Iron therapy in chronic kidney disease: current controversies.
Kovesdy CP; Kalantar-Zadeh K
J Ren Care; 2009 Dec; 35 Suppl 2():14-24. PubMed ID: 19891681
[TBL] [Abstract][Full Text] [Related]
29. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
30. Effect of intravenous iron sucrose on oxidative stress in peritoneal dialysis patients.
Saglam F; Cavdar C; Uysal S; Cavdar Z; Camsari T
Ren Fail; 2007; 29(7):849-54. PubMed ID: 17994454
[TBL] [Abstract][Full Text] [Related]
31. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
[TBL] [Abstract][Full Text] [Related]
32. Intravenous iron-gluconate during haemodialysis modifies plasma beta2-microglobulin properties and levels.
Michelis R; Sela S; Kristal B
Nephrol Dial Transplant; 2005 Sep; 20(9):1963-9. PubMed ID: 15956071
[TBL] [Abstract][Full Text] [Related]
33. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications.
Jahn MR; Andreasen HB; Fütterer S; Nawroth T; Schünemann V; Kolb U; Hofmeister W; Muñoz M; Bock K; Meldal M; Langguth P
Eur J Pharm Biopharm; 2011 Aug; 78(3):480-91. PubMed ID: 21439379
[TBL] [Abstract][Full Text] [Related]
34. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose.
Funk F; Ryle P; Canclini C; Neiser S; Geisser P
Arzneimittelforschung; 2010; 60(6a):345-53. PubMed ID: 20648926
[TBL] [Abstract][Full Text] [Related]
35. Iron sucrose causes greater proteinuria than ferric gluconate in non-dialysis chronic kidney disease.
Agarwal R; Rizkala AR; Kaskas MO; Minasian R; Trout JR
Kidney Int; 2007 Sep; 72(5):638-42. PubMed ID: 17622274
[TBL] [Abstract][Full Text] [Related]
36. Transferrin saturation with intravenous irons: an in vitro study.
Agarwal R
Kidney Int; 2004 Sep; 66(3):1139-44. PubMed ID: 15327409
[TBL] [Abstract][Full Text] [Related]
37. Update on parenteral iron therapy.
Kumpf VJ
Nutr Clin Pract; 2003 Aug; 18(4):318-26. PubMed ID: 16215058
[TBL] [Abstract][Full Text] [Related]
38. On the relative safety of parenteral iron formulations.
Chertow GM; Mason PD; Vaage-Nilsen O; Ahlmén J
Nephrol Dial Transplant; 2004 Jun; 19(6):1571-5. PubMed ID: 15150356
[TBL] [Abstract][Full Text] [Related]
39. Single-dose pharmacokinetics of sodium ferric gluconate complex in iron-deficient subjects.
Seligman PA; Dahl NV; Strobos J; Kimko HC; Schleicher RB; Jones M; Ducharme MP
Pharmacotherapy; 2004 May; 24(5):574-83. PubMed ID: 15162891
[TBL] [Abstract][Full Text] [Related]
40. Safety in iron management.
Fishbane S
Am J Kidney Dis; 2003 Jun; 41(5 Suppl):18-26. PubMed ID: 12776310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
